U.S. Anal Cancer Market Size, Share & Forecast 2026–2032

ID: MR-11481 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Anal Cancer Market
  • ✓Market Size 2024: USD 1.14 billion
  • ✓Market Size 2032: USD 1.90 billion
  • ✓CAGR: 6.6%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Zynyz Breaks Checkpoint Label Gap: Incyte's Zynyz, cleared by the FDA in May 2025 for metastatic squamous cell anal carcinoma, is the only checkpoint inhibitor with a disease-specific anal label. Merck's Keytruda reaches this population only through a tissue-agnostic MSI-H/dMMR label.
FINDING 02
Vaccination Will Not Shrink Demand: Vaccination is widely assumed to shrink treatment demand. Gardasil 9 coverage among U.S. adolescents remains below the 80 percent national target, and treated cases will stay flat through 2032 because most tumors arise from infections acquired decades earlier.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Partnerships Before 2027: Biopharma investors should secure companion-diagnostic and oncology-network partnerships before early 2027, when payers finalise coverage for checkpoint-based anal carcinoma regimens. Enter through a licensing deal rather than a greenfield launch.

Anal Cancer Treatment in the U.S.: Market Overview

The U.S. anal cancer market is a small, specialty-driven segment of oncology, with more than 9,000 new anal cancer diagnoses projected by the American Cancer Society for 2025, most of them squamous cell carcinomas. Standard care is built on definitive chemoradiation using mitomycin and fluorouracil, a regimen dating to the 1980s, so revenue is concentrated in the metastatic and recurrent minority of patients. That structure differs sharply from the global norm, where generic chemotherapy dominates volume in lower-income markets.

Market value reached an estimated USD 1.14 billion in 2024, driven by branded immuno-oncology sales rather than volume growth. Anal cancer incidence is rising fastest among men who have sex with men and people living with HIV, a population concentrated in coastal metropolitan areas such as New York, Los Angeles and Miami, which shapes where specialist capacity and trial sites sit. Revenue per patient in the U.S. is several times the global average because pricing, reimbursement and biologic use are all more expensive.

Growth Drivers in U.S. Anal Cancer Care

First, the FDA's May 2025 approval of Zynyz with carboplatin and paclitaxel created the first disease-specific checkpoint label for metastatic squamous cell anal carcinoma, opening a replacement cycle for community and academic oncologists. Second, CDC routine HPV vaccination recommendations for Gardasil 9 at ages 11 to 12 are building a future cohort, although the effect on treatment demand lags by decades.

Third, HIV care funded through the Ryan White HIV/AIDS Program and the federal Ending the HIV Epidemic initiative is directing more high-risk patients into clinics that perform anal cytology and high-resolution anoscopy, increasing diagnoses. Diagnostic throughput is therefore expanding in the same metropolitan clinics that serve the most exposed population, lifting referral volumes and specialist oncology prescribing.

Market Restraints and Entry Barriers

The most consequential barrier is the absence of USPSTF-recommended anal cancer screening, which keeps most diagnoses at later stages and limits the volume entering treatment. High-resolution anoscopy programmes are concentrated in academic and HIV-focused clinics, and reimbursement for anoscopy and cytology varies by payer, so providers face uneven economics when they add screening capacity.

Pricing and access form the second barrier. Checkpoint inhibitors are reimbursed under Medicare Part B and commercial plans with prior-authorisation rules, while 340B covered-entity pricing diverts discounts away from manufacturers and reduces net revenue on high-volume clinics. Incumbent advantage is also decisive: Merck's Keytruda holds formulary positions and pathway placement, so a new entrant must secure NCCN guideline listing before payers cover it routinely.

Market Opportunities in U.S. Anal Cancer Care

The most immediate opportunity is the first-line metastatic segment, where Zynyz-based combinations compete for patients presenting with distant disease, which SEER data place at roughly 15 percent of diagnoses. Assuming 1,400 treated metastatic patients annually and an average net price of USD 150,000 per treatment course, this segment alone supports roughly USD 210 million of annual drug spend, according to our estimate.

A second opportunity lies in HIV-linked screening and companion diagnostics. High-resolution anoscopy and cytology programmes in New York, Los Angeles and Miami can be scaled through contracts with Ryan White-funded clinics, addressing an estimated 1.2 million people living with HIV who are men who have sex with men. Third-party laboratories offering HPV and cytology testing can capture this flow at the point of referral.

Market at a Glance

MetricValue
Market Size 2024USD 1.14 billion
Market Size 2032USD 1.90 billion
Growth Rate (CAGR)6.6%
Most Critical Decision FactorSecuring NCCN guideline listing and payer coverage
Largest RegionNortheast United States
Competitive StructureBranded oligopoly with a generic chemotherapy tail

Leading Market Participants

  • Merck & Co.
  • Incyte Corporation
  • Bristol Myers Squibb
  • Pfizer
  • Fresenius Kabi
  • Teva Pharmaceuticals
  • Hikma Pharmaceuticals
  • Accord Healthcare
  • Sandoz
  • Cardinal Health

Regulatory and Policy Environment

FDA oversight runs through the Center for Drug Evaluation and Research, which reviews anal cancer biologics under biologics license applications, with standard review targets of 10 months and priority review targets of six months from filing. Zynyz and Keytruda carry supplemental approvals, and accelerated approvals require confirmatory trials. Drug pricing will also shift under the Inflation Reduction Act, whose Medicare negotiation programme extends to high-spend Part B drugs from 2028, placing checkpoint inhibitors such as Keytruda within scope.

HPV vaccination is governed by ACIP recommendations adopted by the CDC, with Vaccines for Children Program supply for eligible under-19s. The 340B Drug Pricing Program, administered by HRSA, requires manufacturers to offer discounts to qualifying clinics, while the Ryan White HIV/AIDS Program, funded at roughly USD 2.5 billion annually, supports the testing and referral infrastructure that feeds anal cancer diagnosis. Biosimilar entry follows the Biologics Price Competition and Innovation Act pathway.

Long-Term Outlook for Anal Cancer Treatment in the U.S.

By 2032 the market is forecast to reach USD 1.90 billion at a CAGR of 6.6 percent, with immunotherapy accounting for most incremental spend as Zynyz and Keytruda combinations move earlier into the treatment pathway. Treatment volumes will grow more slowly than revenue, reflecting biologic price premiums rather than rising patient counts.

Growth will concentrate in the metropolitan HIV clinics of New York, Los Angeles and Miami, where screening and specialist capacity cluster. Vaccination will reduce future incidence among cohorts vaccinated from 2006 onward, but measurable treatment-volume declines will not appear before the mid-2030s, so near-term returns will depend on checkpoint and companion diagnostic penetration.

Frequently Asked Questions

Licensing or co-promotion with an existing checkpoint inhibitor holder avoids the cost of a biologics licence application. It also gives immediate access to established oncology networks and guideline positioning.
Our estimate places annual drug spend in first-line metastatic disease at roughly USD 210 million. Growth in this segment depends on uptake of combination regimens rather than on incidence changes.
Medicare Part B and commercial payers control reimbursement through prior-authorisation rules and NCCN listing. Specialty pharmacies and 340B covered-entity clinics shape net pricing for high-volume sites.
FDA standard review targets 10 months from filing and priority review targets six months. Accelerated approvals also require confirmatory trials that extend commercial obligations after launch.
New York, Los Angeles and Miami combine high HIV prevalence with dense specialist capacity and trial sites. Partnerships with Ryan White-funded clinics in these cities offer the fastest route to referral volume.

Market Segmentation

By Product Type
  • Immunotherapy
  • Chemotherapy
  • Radiation Therapy
  • Prophylactic Vaccines
  • Diagnostic Testing
By Disease Setting
  • Localized Disease
  • Locally Advanced Disease
  • Metastatic Disease
  • Recurrent Disease
By Care Setting
  • Academic Cancer Centers
  • Community Oncology Practices
  • HIV Care Clinics
  • Hospital Outpatient Departments
  • Specialty Pharmacies

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Anal Cancer Market - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Immunotherapy
4.2 Chemotherapy
4.3 Radiation Therapy
4.4 Prophylactic Vaccines
4.5 Others
Chapter 05 Disease Setting Insights
5.1 Localized Disease
5.2 Locally Advanced Disease
5.3 Metastatic Disease
5.4 Recurrent Disease
5.5 Others
Chapter 06 Care Setting Insights
6.1 Academic Cancer Centers
6.2 Community Oncology Practices
6.3 HIV Care Clinics
6.4 Hospital Outpatient Departments
6.5 Specialty Pharmacies
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Merck & Co.
7.2.2 Incyte Corporation
7.2.3 Bristol Myers Squibb
7.2.4 Pfizer
7.2.5 Fresenius Kabi
7.2.6 Teva Pharmaceuticals
7.2.7 Hikma Pharmaceuticals
7.2.8 Accord Healthcare
7.2.9 Sandoz
7.2.10 Cardinal Health
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.